SCHEMBL1890739

SCHEMBL1890739

CN(C)CCNc1ccc(C(=O)Nc2n[nH]c3c2CN(S(=O)(=O)c2cc(F)cc(F)c2)CC3)c(NC(=O)[C@@H]2CCCO2)c1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 3/20 0.50
SMN1; SMN2 Q16637 6/20 0.41
LMNA P02545 5/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41
ALDH1A1 P00352 4/20 0.38
PKM P14618 1/20 0.38
RAB9A P51151 2/20 0.36
NPC1 O15118 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MAPK1 P28482 1/20 0.35
KDM4E B2RXH2 1/20 0.35
PAK4 O96013 1/20 0.35
MET P08581 2/20 0.34
POLB P06746 1/20 0.34
INSR P06213 1/20 0.34
ALK Q9UM73 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1888325 1.00 IGF1R (0.50) IGF1RSMN1; SMN2LMNAKMT2AMEN1
SCHEMBL1888883 0.90 IGF1R (0.51) IGF1RALDH1A1METINSRALK
SCHEMBL1891507 0.90 IGF1R (0.50) IGF1RSMN1; SMN2LMNAKMT2AMEN1
SCHEMBL1894520 0.90 IGF1R (0.50) IGF1RSMN1; SMN2LMNAKMT2AMEN1
SCHEMBL1892322 0.89 IGF1R (0.49) IGF1RKMT2AALDH1A1METPOLB
SCHEMBL1893196 0.89 IGF1R (0.49) IGF1RSMN1; SMN2LMNAKMT2AMEN1
SCHEMBL1891799 0.89 IGF1R (0.49) IGF1RSMN1; SMN2LMNAKMT2AMEN1
SCHEMBL1885578 0.88 IGF1R (0.53) IGF1RSMN1; SMN2LMNAKMT2AMEN1
SCHEMBL1892246 0.88 IGF1R (0.53) IGF1RSMN1; SMN2LMNAKMT2AMEN1
SCHEMBL1889780 0.88 PAK4 (0.40) IGF1RSMN1; SMN2LMNAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110230470-A1 SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-09-22 US disclosed
US-7947686-B2 Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230470-A1 SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K3, MAP3K1, MAP3K19 IGF1R 760/4885SMN1; SMN2 3711/4885LMNA 3253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.